Literature DB >> 28779853

Preliminary psychometric properties of the brief Negative Symptom Scale in youth at Clinical High-Risk for psychosis.

Gregory P Strauss1, Hannah C Chapman2.   

Abstract

Preliminary psychometric properties of an adapted version of the Brief Negative Symptom Scale (BNSS) are reported in youth at Clinical High-Risk for psychosis (CHR). Participants included 29 CHR youth who met criteria for a prodromal syndrome on the Structured Interview for Prodromal Syndromes (SIPS). The adapted BNSS demonstrated excellent internal consistency, convergent validity, and discriminant validity, suggesting that the BNSS has utility for assessing negative symptoms in a CHR population.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Assessment; Negative symptoms; Prodrome; Psychosis

Mesh:

Year:  2017        PMID: 28779853     DOI: 10.1016/j.schres.2017.07.051

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

Review 1.  A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis.

Authors:  Gregory P Strauss; Andrea Pelletier-Baldelli; Katherine Frost Visser; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Res       Date:  2020-06-07       Impact factor: 4.939

2.  Factor Analysis of Negative Symptom Items in the Structured Interview for Prodromal Syndromes.

Authors:  Matilda Azis; Gregory P Strauss; Elaine Walker; William Revelle; Richard Zinbarg; Vijay Mittal
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

3.  Emotion regulation across the psychosis continuum.

Authors:  Hannah C Chapman; Katherine F Visser; Vijay A Mittal; Brandon E Gibb; Meredith E Coles; Gregory P Strauss
Journal:  Dev Psychopathol       Date:  2020-02

4.  The Latent Structure of Negative Symptoms in Individuals With Attenuated Psychosis Syndrome and Early Psychosis: Support for the 5 Consensus Domains.

Authors:  Wing Chung Chang; Gregory P Strauss; Anthony O Ahmed; Sandra C Y Wong; Joe K N Chan; Edwin H M Lee; Sherry K W Chan; Christy L M Hui; Sydney H James; Hannah C Chapman; Eric Y H Chen
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

5.  Validation of accelerometry as a digital phenotyping measure of negative symptoms in schizophrenia.

Authors:  Gregory P Strauss; Ian M Raugh; Luyu Zhang; Lauren Luther; Hannah C Chapman; Daniel N Allen; Brian Kirkpatrick; Alex S Cohen
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-15

6.  A Meta-Analysis of Neuropsychological Effort Test Performance in Psychotic Disorders.

Authors:  Ivan Ruiz; Ian M Raugh; Lisa A Bartolomeo; Gregory P Strauss
Journal:  Neuropsychol Rev       Date:  2020-08-07       Impact factor: 7.444

7.  FRONTAL ALPHA ASYMMETRY IN YOUTH AT CLINICAL HIGH-RISK FOR PSYCHOSIS.

Authors:  Lisa A Bartolomeo; Molly A Erickson; Lauren E Arnold; Gregory P Strauss
Journal:  Curr Behav Neurosci Rep       Date:  2019-05-07

8.  Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study.

Authors:  D J Devoe; L Lu; T D Cannon; K S Cadenhead; B A Cornblatt; T H McGlashan; D O Perkins; L J Seidman; M T Tsuang; S W Woods; E F Walker; D H Mathalon; C E Bearden; J Addington
Journal:  Schizophr Res       Date:  2020-04-30       Impact factor: 4.939

9.  Reinforcement learning abnormalities in the attenuated psychosis syndrome and first episode psychosis.

Authors:  Gregory P Strauss; Raktima Datta; William Armstrong; Ian M Raugh; Nina V Kraguljac; Adrienne C Lahti
Journal:  Eur Neuropsychopharmacol       Date:  2021-04-02       Impact factor: 5.415

10.  Pilot Validation Study of the Japanese Translation of the Brief Negative Symptoms Scale (BNSS).

Authors:  Naoki Hashimoto; Atsuhito Toyomaki; Matsuhiko Oka; Keisuke Takanobu; Ryo Okubo; Hisashi Narita; Kan Kitagawa; Niki Udo; Tamaki Maeda; Shinya Watanabe; Yuka Oyanagi; Akane Miyazaki; Koki Ito; Ichiro Kusumi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-12-23       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.